Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-08-04
2009-10-27
Yaen, Christopher H (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Reexamination Certificate
active
07608685
ABSTRACT:
A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.
REFERENCES:
patent: 5622835 (1997-04-01), Herlyn et al.
patent: 5726288 (1998-03-01), Call et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6207880 (2001-03-01), Kossmann et al.
patent: 7030212 (2006-04-01), Sugiyama et al.
patent: 2003/0039635 (2003-02-01), Gaiger et al.
patent: 2003/0072767 (2003-04-01), Gaiger et al.
patent: 2003/0082196 (2003-05-01), Gaiger et al.
patent: 2003/0092656 (2003-05-01), Sugiyama
patent: 2003/0095971 (2003-05-01), Gaiger et al.
patent: 2003/0198622 (2003-10-01), Gaiger et al.
patent: 2003/0215458 (2003-11-01), Gaiger et al.
patent: 2003/0235557 (2003-12-01), Gaiger et al.
patent: 2004/0018204 (2004-01-01), Gaiger et al.
patent: 2004/0097703 (2004-05-01), Sugiyama
patent: 2004/0126362 (2004-07-01), Gaiger et al.
patent: 2004/0247609 (2004-12-01), Sugiyama
patent: 2005/0002951 (2005-01-01), Sugiyama et al.
patent: 2006/0093615 (2006-05-01), Sugiyama et al.
patent: 1 004 319 (1998-07-01), None
patent: 1 074 267 (2000-07-01), None
patent: 1 103 564 (2001-05-01), None
patent: 61-22018 (1986-01-01), None
patent: 09-104629 (1997-04-01), None
patent: 2001-89389 (2001-04-01), None
patent: WO 91/07509 (1991-05-01), None
patent: WO 95/16464 (1995-06-01), None
patent: WO 95/29995 (1995-11-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 96/38176 (1996-12-01), None
patent: WO 99/44634 (1999-09-01), None
patent: WO 00/06602 (2000-02-01), None
patent: WO 00/18795 (2000-04-01), None
patent: WO 00/26249 (2000-05-01), None
patent: WO 00/41463 (2000-07-01), None
patent: WO 00/44349 (2000-08-01), None
patent: WO 01/62920 (2001-08-01), None
patent: WO 02/79253 (2002-10-01), None
patent: WO 03/106682 (2003-12-01), None
Ezzell (J. NIH Res, 1995, 7:46-49).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Boon (Adv Can Res, 1992, 58:177-210).
DeGruijl et al (Nature Medicine, 5410): 1124-1125, Oct. 1999).
Bodey et al (Anticancer Research. 20:2665-2676; 2000).
Gaiger et al. (Blood, vol. 96, No. 4, Aug. 2000, pp. 1480-1489.
F. J. Rauscher, III, et al., “Characterization of Monoclonal Antibodies Dirrected to the Amino-Terminus of the WT1, Wilms' Tumor Suppressor Protein”, Hybridoma, vol. 17, No. 2, Apr. 1998, pp. 191-198.
H. G. Rammensee, et al., “Peptides Naturally Presented by MHC Class I Molecules”, Ann. Rev. Immunol, 1993, pp. 213-244.
A. J. Buckler, et al., “Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Devleopment”, Molecular and Cellular Biology, vol. 11, No. 3, 1991, pp. 1707-1712.
D.M. Pardoll, “New Strategie for Enhancing the Immunogenicity of Tumors”, Current Opinion in Immunology, vol. 5, No. 5, 1993, pp. 719-725.
C.M. Melief, et al., “Potential Immunogenicity of Oncogenea and Tumor Suppressor Gene Products”, Current Opinion in Immunology, vol. 5, No. 5, 1993, pp. 709-713.
H.G. Rammensee, et al., “MHC Ligands and Peptide Motifs: First Listing”, Immunogenetics, vol. 41, No. 4, 1995, pp. 178-228.
B. Palermo, et al., “Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a Qualitative Analysis”, Melanoma Research, 2002, 12. pp. 491-498.
L. Gao, et al, “Selective Elimination of Leukemic CD34+Progenitor Cells by Cytotoxic T Lymphocytes Specific for WT1”, Blood, Apr. 1, 2000, vol. 95, No. 7, pp. 2198-2203.
N. Renkvist, et al., “A Listing of Human Tumor Antigens Recognized by T Cells”, Cancer Immunol. Immunother, 2001, 50: pp. 3-15.
M. Gessler, et al., “Homozygous Deletion in Wilms Tumours of a Zinc-Finger Gene Identified by Chromosome”, Nature, vol. 343, Feb. 22, 1990, pp. 774-778.
A. Tsuboi, et al., “Cytotoxic T-Lymphocyte Responses Elicited to Wilms' Tumor Gene WT1 Product by DNA Vaccination”, Journal of Clinical Immunology, vol. 20, No. 3, 2000, pp. 195-202.
A. Gaiger, et al., “Immunity of WT1 in the Animal Model and in Patients with Acute Myeloid Leukemia”, Aug. 15, 2000, vol. 96, No. 4, pp. 1480-1489.
W. Barclay, et al., “Effects of Oil-Treated Mycobacterial Cell Walls of the Organs of Mice”, Journal of Bacteriology, No. 1967, pp. 1736-1745.
M. Yamawaki, et al., “Antitumor Activity of Squalene-Treated Cell-Wall Skeleton of Nocardia Rubra in Mice”, Gann, vol. 69, No. 5, pp. 619-626.
Y. Oka, et al., XP-000884935, vol. 51, No. 2, Feb. 1, 2000, “Human Cytotoxic T-Lymphocyte Responses Specific for Peptides of the Wild-Type Wilms' Tumor Gene (WT1) Product”.
M. Yasukawa, et al., “HLA Class I-Restricted Lysis of Leukemia Cells by a CD8+Cytotoxic T-Lymphocyte Clone Directed Against WT1 Peptide”, Blood, Nov. 15, 1998, vol. 92, No. 10, Part 1, Suppl. 1: Abstract p. 2541.
Gura, “Systems for Identifying New Drugs Are Often Faulty”, Science, vol. 278, 1997, pp. 1041-1042.
M. Bellone, et al., “Cancer Immunotherapy: Synthetic and Natural Peptides in the Balance”, Immunology Today, vol. 20, No. 10, Oct. 1999, pp. 457-461.
A. Gaiger, et al., “Immunity to WT1 in the Animal Model and In Patients with Acute Myeloid Leukemia”, Blood, vol. 96, No. 4, Aug. 15, 2000, pp. 1480-1489.
A. Gaiger, et al., “WT1: A New Leukemia and Cancer Antigen”, Proceeding of the American Association for Cancer Research Annual Meeting, vol. 40, Mar. 1999, p. 424.
Patent Family Information of Attached Reference WO 00/18795.
Patent Family Information of Attached Reference WO 00/26249.
I. Roitt, et al., Immunology, 4thEd., 1996, Mosby, pp. 7.9-7.11.
Y. Oka, et al., “Induction of WT1 (Wilms' Tumor Gene)-specific Cytotoxic T Lymphocytes by WT1 Peptide Vaccine and the Resultant Cancer Regression”, 2004, vol. 101, No. 38, pp. 13885-13890.
I. Higashi, Biomedicine & Therapeutics, 1988, vol. 20, No. 1, pp. 21-26, “BRM to shite no Saikln Kintai Seibun”.
B. Zbar, et al., “Tumor Suppression by Cell Walls of Mycobacterium Bovis Attached to Oil Droplets1”, Journal of the National Cancer Institute, vol. 48, No. 3, Mar. 1972, pp. 831-835.
M. Singh, et al., “Advances in Vaccine Adjuvants”, Nature Biotechnology, vol. 17, Nov. 17, 1999, pp. 1075-1081.
F. Nestle, et al., Vaccination of Melanoma Patients with Peptide- or Tumor Lysate-Pulsed Dendritic Cells, Nature Medicine, vol. 4, No. 3, Mar. 1998, pp. 328-332.
L. Chedid, et al., “Protective Effect of Delipidated Mycobacterial Cells and Purified Cell Walls Against Ehrlich Carcinoma and a Syngeneic Lymphoid Leukemia in Mice1”, Cancer Research, 33, Sep. 1973, pp. 2187-2195.
C. Melief, et al., “T-Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination wit Minimal Essential Epitopes”, Immunological Reviews, 1995, No. 146, pp. 167-177.
Y. Oka, et al., Hematology Frontier, 2000, vol. 10, No. 8, pp. 1017-1023, “3. Men'eki Ryoho 2) WT1 o Hyotekki to shita Hakketsubyo ni Taisuru Tokuiteki Men'eki Ryoho”.
E. Ribi, et al., “Factors Influencing Protection Against Experimental Ruberculosis in Mice by Heat-Stable Cell Wall Vaccines”, Journal of Bacteriology, Oct. 1966, vol. 92, No. 4, pp. 868-879.
H. Suglyama, “Wilms' Tumor Gene WT1: Its Oncogenic Function and Clinical Application” International Journal of Hematology, vol. 73, 2001, pp. 177-187.
R. Lin, et al., “Present Status of the Use of Cytokines as Adjuvants with Vaccines to Protect Against infectious Diseases”, Clin. Infect. Dis., vol. 21, No. 6, 1995, pp. 1439-1449.
Y. Tanio, Partial Englis Translation of Japanese Journal of Cancer and Chemotherapy, vol. 7, No, 9, pp. 1710-1718, 1980.
T. Azuma, et
Oka Yoshihiro
Sugiyama Haruo
International Institute of Cancer Immunology, Inc.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Yaen Christopher H
LandOfFree
Tumor antigen based on products of the tumor suppressor gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor antigen based on products of the tumor suppressor gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen based on products of the tumor suppressor gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061429